<DOC>
	<DOCNO>NCT02361112</DOCNO>
	<brief_summary>Pyrotinib oral tyrosine kinase inhibitor target EGFR HER-2 receptor . This study design evaluate safety tolerability Pyrotinib combination capecitabine patient HER2 positive metastatic breast cancer : To evaluate safety tolerability pyrotinib , maximum tolerate dose ( MTD ) To determine dose-limiting toxicity ( DLT ) To determine pharmacokinetic profile Pyrotinib To assess preliminary antitumor activity To determine preliminary regimen dose phase II study</brief_summary>
	<brief_title>Study Evaluating Pyrotinib Combination With Capecitabine In Patients With HER2 Positive Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Aged ≥18 ≤70 year . ECOG performance status 0 1 . Life expectancy 12 week . At least one measurable lesion exists . ( RECIST 1.1 ) Histologically cytologic confirm HER2 positive metastatic breast cancer fail prior therapy . No previous treatment capecitabin past 1 year . Required laboratory value include follow parameter : ANC : ≥ 1.5 x 109/L Platelet count : ≥ 100 x 109/L Hemoglobin : ≥ 9.0 g/dL Total bilirubin : ≤ 1.5 x upper limit normal , ULN ALT AST : ≤ 1.5 x ULN BUN creatine clearance rate : ≥ 50 mL/min LVEF : ≥ 50 % QTcF : &lt; 470 m Signed informed consent . Subjects third space fluid control drainage method . Steroid treatment 50 day , need longterm use steroid . Subjects unable swallow tablet , dysfunction gastrointestinal absorption . Less 4 week last radiotherapy , chemotherapy，surgery，hermone treatment , target therapy , less 6 week nitrosoureas mitomycin chemotherapy . Subjects efficacy previous treatment capecitabine . Subjects uncontrolled hypokalemia hypomagnesemia study entry . Subjects interrupt use drug may cause QT prolongation study . Subjects intracranial lesion . Subjects bone skin target lesion Treated treat HER2 tyrosine kinase inhibitor ( TKIs ) study entry . Receiving antitumor therapy . Less 4 week last clinical trial . Known history hypersensitivity pyrotinib、capecitabine component metabolites . Ongoing infection ( determined investigator ) . History immunodeficiency , include HIVpositive , suffer acquire , congenital immunodeficiency disease , history organ transplantation . Subjects heart disease , include : ( 1 ) angina ; ( 2 ) require medication clinically significant arrhythmia ; ( 3 ) myocardial infarction ; ( 4 ) heart failure ; ( 5 ) Any heart disease judge investigator unsuitable participate trial . Female patient pregnancy , lactation woman childbearing potential test positive baseline pregnancy test . Female patient childbearing age reluctant take effective contraceptive measure throughout trial period . Evidence significant medical illness investigator 's judgment substantially increase risk associate subject 's participation completion study . Examples include , limited , hypertension , severe diabetes , thyroid disease . Alcoholism , smoking ( daily ≥ 5 root ) bad habit . Known history neurological psychiatric disease , include epilepsy dementia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>